AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

CHESNARA PLC

Director's Dealing Apr 29, 2020

5301_dirs_2020-04-29_cb5e62e4-cc2b-4a44-b137-232324c257e1.html

Director's Dealing

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 2099L

Chesnara PLC

29 April 2020

CHESNARA plc

("Chesnara" or "the Company")

29 April 2020

LEI Number: 213800VFRMBRTSZ3SJ06

NOTIFICATION OF TRANSACTIONS OF DIRECTORS / PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY ('PDMRs')

Chesnara plc (the 'Company') today announces that, as at 28 April 2020, John Deane and David Rimmington (each a PDMR) were granted awards in the ordinary shares of the Company under the Chesnara plc Long Term and Short Term Schemes.  These awards were made in accordance with the Directors' Remuneration Policy.

The notifications for each PDMR below, which are being made in accordance with the requirements of the EU Market Abuse Regulations, provide further detail of the awards granted to each PDMR.

1 Details of the person discharging managerial responsibilities/person closely associated
a)

b)
Natural person:                

Legal person
John Deane
2 Reason for the notification
a) Position/status: Chief Executive Officer
b) Initial notification/amendment Initial notification
3 Details of the Issuer
a) Name Chesnara plc
b) Legal Entity Identifier: 213800VFRMBRTSZ3SJ06
4 Details of the transaction(s): Parts a-d of this section are to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted.
a) Description of the financial instrument, type of instrument (Identification code) Chesnara plc Ordinary Shares of 5 pence each

(GB00B00FPT80)
b) Nature of the transaction GRANT 1

Granted under the Chesnara 2014 Short-term Incentive Scheme. The option is not subject to a performance target.

The option will become exercisable on 28 April 2023 and remain exercisable up to and including 27 April 2030 if not exercised before that date.

GRANT 2

Granted under the Chesnara 2014 Long-term Incentive Scheme. The option is subject to a performance target over a period of three financial years.

Subject to the achievement of the performance target, the option will become exercisable on 28 April 2023 and remain exercisable up to and including 27 April 2030 if not exercised before that date.
c) Price(s) and volume(s) Price(s) Volume(s)
Nil GRANT 1

48,491 Ordinary shares of 5p each
Nil GRANT 2

143,045 Ordinary shares of 5p each
d) Aggregated information

- Aggregated volume

- Price
-    191,536 ORDINARY SHARES OF 5P EACH

-    Nil
e) Date of the transaction (YYYY - MM - DD) 2020-04-28
f) Place of the transaction XOFF
1 Details of the person discharging managerial responsibilities/person closely associated
a)

b)
Natural person:                

Legal person
David Rimmington
2 Reason for the notification
a) Position/status: Chief Finance Officer
b) Initial notification/amendment Initial notification
3 Details of the Issuer
a) Name Chesnara plc
b) Legal Entity Identifier: 213800VFRMBRTSZ3SJ06
4 Details of the transaction(s): Parts a-d of this section are to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted.
a) Description of the financial instrument, type of instrument (Identification code) Chesnara plc Ordinary Shares of 5 pence each

(GB00B00FPT80)
b) Nature of the transaction GRANT 1

Granted under the Chesnara 2014 Short-term Incentive Scheme. The option is not subject to a performance target.

The option will become exercisable on 28 April 2023 and remain exercisable up to and including 27 April 2030 if not exercised before that date.

GRANT 2

Granted under the Chesnara 2014 Long-term Incentive Scheme. The option is subject to a performance target over a period of three financial years.

Subject to the achievement of the performance target, the option will become exercisable on 28 April 2023 and remain exercisable up to and including 27 April 2030 if not exercised before that date.
c) Price(s) and volume(s) Price(s) Volume(s)
Nil GRANT 1

27,418 Ordinary shares of 5p each
Nil GRANT 2

81,213 Ordinary shares of 5p each
d) Aggregated information

- Aggregated volume

- Price
108,631 ORDINARY SHARES OF 5P EACH

Nil
e) Date of the transaction (YYYY - MM - DD) 2020-04-28
f) Place of the transaction XOFF

Name of authorised official of issuer responsible for making notification: - Al Lonie

Date of notification: - 29 April 2020  

For further information, please contact:

Roddy Watt

Director, Capital Markets

FWD

Forward thinking communications

T   -    020 7280 0651  

E   -    [email protected] 

Notes to Editors

Chesnara is a life and pensions company listed on the London Stock Exchange. It administers over one million policies with those assets spread broadly equally across businesses in the UK, the Netherlands and Sweden. Chesnara operates as Countrywide Assured in the UK, as The Waard Group and Scildon in the Netherlands, and as Movestic in Sweden.

Following a three pillar strategy, Chesnara's primary responsibility is the efficient administration of its customers' life and savings policies, ensuring good customer outcomes and providing a secure and compliant environment to protect policyholder interests. It also adds value by writing profitable new business in Sweden and the Netherlands and by undertaking value-adding acquisitions of either companies or portfolios.

Consistent delivery of the Company strategy has enabled Chesnara to increase its dividend for 15 years in succession.

Further details are available on the Company's website (www.chesnara.co.uk ).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHPPUACCUPUGCR

Talk to a Data Expert

Have a question? We'll get back to you promptly.